Porvair has developed a 2-ml 96 round-well deep-well plate that enables scientists to use the full 2.00 ml well capacity.
Visitors can view a range of application optimized microplates and microplate equipment at Porvair Sciences’ stand. For laboratories involved with fraction collecting, compound storage, plate replication, and mixing applications, Porvair has developed a 2-ml 96 round-well deep-well plate that enables scientists to use the full 2.00 ml well capacity. Manufactured under class 10,000 conditions from ultra-pure grade polypropylene these plates are certified as RNase/DNase free and contain no measurable contaminants that could otherwise leach out and affect the sample, according to Porvair. â¨â¨
Also on display is the Ultravap Levante, which is the latest edition in Porvair’s series of nitrogen blow-down sample concentrators and evaporators. Using technology from the Ultravap Mistral series of robot-ready, integration-compatible evaporators, Porvair has re-designed the classic single plate evaporator to meet the needs of the modern laboratory. The Ultravap Levante and Ultravap Mistral make it easier to integrate an automatic dry down step into an automated liquid handling protocol.
In addition, Porvair is exhibiting its extensive range of reagent reservoirs and deep well, shallow well, storage, assay, SPE, protein precipitation and filtration microplates precisely manufactured to comply with ANSI/SLAS dimensions. â¨â¨
Source: Porvair Sciences, Hall 4.2, Stand F44
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.